BrightPath Biotherapeutics Co., Ltd. (TSE:4594) announced a private placement of 44,800 units of 12th series warrants at a price of ¥222 per warrant for proceeds of ¥9,945,600 and 11,200 units of 13th series warrants at a price of ¥199 per warrant for proceeds of ¥2,228,800; for aggregate gross proceeds of ¥12,174,400 on November 22, 2017. Each warrant is exercisable at a price of ¥720 per warrant from December 11, 2017 to December 10, 2019. The transaction will include participation from Credit Suisse Securities (Japan) Limited, Investment Arm. The warrants will be issued by way third party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close on December 8, 2017.